openPR Logo
Press release

Ventricular Tachycardia Treatment Market Revenue Growth Predicted by 2025

03-24-2018 06:24 AM CET | Health & Medicine

Press release from: Persistence Market Research

Ventricular Tachycardia Treatment Market Revenue Growth

Ventricular tachycardia is a life threatening heart condition in which arrhythmic heart beats occur in the ventricles. The two lower chambers of the heart are known as ventricles. They are responsible for supplying the blood received from atria to different parts of the body. When a person suffers from ventricular tachycardia, a high pulse with more than 100 beats per minute is registered with minimum 3 irregular heartbeats experienced in a row. It is most commonly indicated in patients having acute myocardial infarction, electrolyte abnormalities and idiopathic ventricular arrhythmia in heart. Ventricular tachycardia should be correctly diagnosed in time as it may lead to hemodynamic instability causing ventricular fibrillation, thereby becoming a major reason behind deaths due to cardiac attacks. Ventricular tachycardia can be further classified into four different types which includes monomorphic, polymorphic, sustained and non-sustained ventricular tachycardia.

Request for Table of Contents @ https://www.persistencemarketresearch.com/toc/17389

In non-sustained ventricular tachycardia, heartbeat stops impulsively without disturbing the blood flow; whereas, in sustained ventricular tachycardia arrhythmic heartbeats persists for more than 30 seconds and they usually disrupts the blood flow by lowering it. However, in monomorphic ventricular tachycardia, the heartbeats follow a same rhythmic wave pattern and rhythmic pattern varies in case of polymorphic ventricular tachycardia. People who previously had a heart attack or suffers from heart conditions such as myocardial infarction, structural heart disease, ischemic heart disease and are older in age are more likely at the risk of experiencing ventricular tachycardia. Some of the main symptoms for ventricular tachycardia includes fatigue, chest pain, fainting, shortened breath, dizziness, palpitations, cardiac arrests and seizures. It needs to be properly diagnosed in time by performing following diagnostic tests such as electrocardiogram; cardiac imaging which includes echo, MRI, CT scan, coronary angiogram and chest X-ray; stress test; electrophysiological test and other tests.

Depending upon the symptoms and severity of heart disorder, ventricular tachycardia treatment is broadly classified into two categories: emergency treatment for patients in distress and long-term treatment. Various anti-arrhythmic drugs such as Aminodarone, Lidocaine, Sotalol, Procainamide and Nifekalant are most commonly preferred to treat patients with ventricular tachycardia. These drugs treat unusual heart rhythms that originates due to error in electrical activity of heart. 

Rising incidence of heart injuries such as myocardial infarctions and valvular heart disease is anticipated to be the primary factor fueling the ventricular tachycardia treatment market. Growing geriatric population with rising heart conditions such as heart attacks, changing lifestyle, rising inclination of patients for cardiomyopathy and heart surgery are some other factors which further drive the ventricular tachycardia treatment market. Moreover, advancing technology and enhanced treatment therapies is further anticipated to drive the market over forecast period. However, high costs associated with heart surgeries is restraining the current market growth.

On the basis of type of treatment, catheter ablation is most common treatment technique used to restore common rhythmic heartbeats. Also, owing to the promising success rates associated with catheter ablation treatment procedure, it is further anticipated to dominate over the forecast period.

Based on geography, global ventricular tachycardia treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America registered for the largest shares in global ventricular tachycardia treatment market followed by Europe and Asia-Pacific. North America region is anticipated to continue the same trend on the account of rise in number of deaths due to cardiac fatalities in U.S.

Request a Sample Brochure of the Report @ https://www.persistencemarketresearch.com/samples/17389

Some of the key players involved in global ventricular tachycardia treatment market are INOVYTEC MEDICAL SOLUTIONS Ltd., CU Medical Systems, Inc., Cardiac Science Co., Bexen Cardio, Advanced Instrumentations Inc., Baxter International Inc., Pfizer Inc., Heritage Pharmaceuticals Inc. and others.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

Telephone - +1-646-568-7751

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ventricular Tachycardia Treatment Market Revenue Growth Predicted by 2025 here

News-ID: 991081 • Views: 221

More Releases from Persistence Market Research

Global Waterborne Coatings Market Revenue to Witness Steady Growth Through 2020
Waterborne coatings are green substrates using water as solvent to dissolve a resin, making them environment friendly and easy to apply. These coatings usually contain approximately 80% of water with minimum quantities of other solvents such as glycol ethers. As per the U.S. and European regulations of waterborne coatings to have a VOC content less than 3.5 gallons of water, these are considered eco-friendly in nature. Various types of coatings
Manufacturers to Benefit from Lucrative Growth Prospects in the Global Textile P …
Application of coloring pattern and design to decorate the finished fabric is referred as printing. At the time of printing the color is applied to the fabric so that the color or design is not affected at the time of washing. Textile printing is a process of applying color to fabric in definite pattern and design. Textile printing is sometime confused with dyeing. In dyeing whole fabric is uniformly colored
Demand for Triazole Fungicides to Rise Significantly from Key End-use Industry S …
The growth of the crop can be affected by fungal infection. Fungicides are chemical compound used to kill fungi or fungal spores. Triazole is most widely used fungicides due to their different uses and efficacy against a number of fungal diseases. Triazole is highly effective against many different fungal diseases include rusts, leaf-spotting fungi and powdery mildews. Triazole is used on field crops, fruit trees and vegetables. Repeated use
Global Purified Terephthalic Acid Market Revenue to Witness Rapid Growth in the …
Purified terephthalic acid (PTA) is a chemical which is synthesized from crude oil. It is majorly used to manufacture polyester fiber. Its end-user industries include textile and home furnishing where PTA is required to manufacture garments such as bed sheets, curtains and clothes. Request For Report Sample@https://www.persistencemarketresearch.com/samples/3434 The market for purified terephthalic is expected to witness noticeable expansion in the coming years with the growing demand for polyester, specifically in

All 5 Releases


More Releases for Ventricular

Latest Evolution of Ventricular Drainage Sets Market Analysis 2026
Ventricular Drainage Sets Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Ventricular Drainage Sets market research report is a professional and in-depth study on the current state of Ventricular Drainage Sets Industry. The Ventricular Drainage Sets Market research report covers the present scenario and
Left Ventricular Dysfunction - Pipeline Review, H1 2018
Left Ventricular Dysfunction Overview Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart beat and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism and Left Ventricular Dysfunction. Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811435-left-ventricular-dysfunction-pipeline-review-h1-2018 Top Companies mentioned Bayer AG Innopharmax Inc Mesoblast Ltd Novartis AG Quantum Genomics SA TiGenix NV Left Ventricular Dysfunction Industry Major Outlook Pharmaceutical and Healthcare latest pipeline guide Left Ventricular Dysfunction -
Ventricular Tachycardia Market Forecast Report Offers Actionable Insights 2017 - …
Ventricular tachycardia is a condition, wherein the pulse rate is more than 100 beats per minute with minimum three continuous irregular heartbeats. This condition occurs in bottom chambers of the heart and develops as an early or late complication of heart attack. Patients suffering from cardiomyopathy, myocarditis, or valvular heart disease are at a higher risk of developing ventricular tachycardia. Major reasons for ventricular tachycardia are changes in pH values,
Left Ventricular Dysfunction - Pipeline Review, H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2017, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape. Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart beat and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism and coronary artery disease. Report Highlights Publisher's Pharmaceutical and Healthcare
Ventricular Tachycardia Treatment Market And Segment Forecasts To 2017 – 2025
Ventricular tachycardia is a life threatening heart condition in which arrhythmic heart beats occur in the ventricles. The two lower chambers of the heart are known as ventricles. They are responsible for supplying the blood received from atria to different parts of the body. When a person suffers from ventricular tachycardia, a high pulse with more than 100 beats per minute is registered with minimum 3 irregular heartbeats experienced in
05-08-2017 | Health & Medicine
SA-BRC
Ventricular Assist Devices (VAD) Market Assessment
Ventricular assist devices (VAD) are mechanical pumps used to support patients with a weakened heart or in case of heart failure to temporarily maintain heart function. The devices helps in re-establishing normal hemodynamics under conditions involving damaged ventricle. Increasing trend for sedentary lifestyle, rising obesity population globally, lifestyle changes and various other factors have resulted an increase in cardiovascular disorders. This rising prevalence across the globe has been a major